Featured Tickers:
Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Alvotech, Grifols or S.A. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how Alvotech, Grifols and S.A. compare based on key financial metrics to determine which better meets your investment needs.
About Alvotech, Grifols and S.A.
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo IDP, an immunology drug; Yimmugo PTI, a hematology drug; and Prolastin vials, a pulmonology drug. Further, it develops Xembify Pre-filled syringes, Gamunex Bags, and FlexBag that are in LCM stage; Xembify Biweekly dosing, Fibrinogen, and VISTASEAL which are in regulatory stage; Prolastin-C AADT and Fostamatinib that are in Phase IV; Xembify – CLL, Albumina 20% and 5%, and Trimodulin which are in Phase III; Alfa-1 AT 15%, GRF6019, GRF6021, Aßvac402, AKST4290, and AKST4290 that are in Phase II; GIGA 2339 and GIGA564 which are in Phase I; and recIG, Alfa-1 AT – in non-cystic fibrosis bronchiectasis, and OSIG that are in pre-clinical stage. It has collaboration agreements with Canadian Blood Services to supply grains of Immunoglobulin. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Latest Biotechnology and Alvotech, Grifols, S.A. Stock News
As of March 28, 2025, Alvotech had a $2.9 billion market capitalization, compared to the Biotechnology median of $102.3 million. Alvotech’s stock is down 27.8% in 2025, down 17.4% in the previous five trading days and down 23.6% in the past year.
Currently, Alvotech does not have a price-earnings ratio. Alvotech’s trailing 12-month revenue is $492.0 million with a -47.1% net profit margin. Year-over-year quarterly sales growth most recently was 177.2%. Analysts expect adjusted earnings to reach $-0.364 per share for the current fiscal year. Alvotech does not currently pay a dividend.
As of March 28, 2025, Grifols, S.A. had a $5.8 billion market cap, putting it in the 73rd percentile of all stocks. Grifols, S.A.’s stock is down 1.9% in 2025, down 6.4% in the previous five trading days and up 12.19% in the past year.
Currently, Grifols, S.A.’s price-earnings ratio is 30.5. Grifols, S.A.’s trailing 12-month revenue is $7.5 billion with a 2.2% net profit margin. Year-over-year quarterly sales growth most recently was 4.6%. Analysts expect adjusted earnings to reach $0.834 per share for the current fiscal year. Grifols, S.A. does not currently pay a dividend.
How We Compare Alvotech, Grifols and S.A. Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Alvotech, Grifols and S.A.’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions